246: Computational Pathology Is Changing Companion Diagnostics

Send us Fan Mail Can a treatment decision depend on whether one pathologist sees 45% biomarker positivity and another sees 55%? Visual immunohistochemistry scoring helped establish precision oncology. But as targeted therapies become more sensitive to subtle biological differences, categorical scores such as 0, 1+, 2+, and 3+ may no longer capture the information needed to identify the right patients. In this episode, I speak with three Roche experts: Gordana Juric-Sekhar, MD, anatomic pathol...